Rogier Rooswinkel PhD
General Partner
A biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.
Enterprise Therapeutics is a biopharmaceutical company dedicated to the research and development of novel therapies for the treatment of respiratory diseases such as cystic fibrosis, asthma and COPD where the lungs become congested with thick mucus leading to difficulty in breathing.
Enterprise’s scientific strategy is aimed at discovering new disease modifying therapies (by interfering with novel muco-regulatory pathways) that target the underlying mechanisms of mucus congestion, which will reduce the frequency of lung infections and improve patient quality of life.
Human Health
UK
Sussex Innovation Centre
University of Sussex
Science Park Square
Falmer
Brighton, BN1 9SB
Industry
Biotech
Status
Current
Location
UK
I have had the pleasure of working with Forbion from the first day they were established. Along the way we have secured several successful exits and one drug, obicetrapib, is about to be submitted for approval in CV disease. At Enterprise Tx we are working hard to bring a cure to people with cystic fibrosis not treated by Vertex CFTR therapy and other muco-obstructive lung diseases such as COPD. The Phase 2 CF trial for our lead drug ETD001 will read out in early 2026.John Ford
CEO of Enterprise Therapeutics
2026
read out of Phase 2 CF trial
Forbion team
Geert-Jan Mulder MD
Managing Partner